Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Phaxiam Therapeutics S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative bacteriophage-based therapies aimed at combating severe and resistant bacterial infections. The company is noted for its pioneering use of phages—natural viruses that selectively infect and destroy bacteria—which represents a targeted response to the growing challenge of antibiotic resistance. Phaxiam Therapeutics focuses its research on three of the most problematic bacteria linked to hospital-acquired infections: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. These pathogens are responsible for a significant proportion of serious resistant infections globally. Through its specialized portfolio, Phaxiam addresses urgent needs in the healthcare sector, contributing to advances in infectious disease treatment where conventional antibiotics are increasingly ineffective. The company’s strategy and research have established it as a notable player within the biotechnology and medical research industries, particularly in the subsector of anti-infective therapeutics leveraging biological mechanisms for precision targeting of drug-resistant pathogens.
Select a linked metric to explore its chart.